
PRESS RELEASE

AREVA Med acquires Macrocyclics, Inc.

Bethesda, Md., October 20, 2011 – AREVA announced today that its nuclear medicine subsidiary, AREVA Med, has acquired Macrocyclics, Inc.

AREVA Med has developed innovative methods for producing lead-212 (^{212}Pb), a rare radioactive isotope at the heart of promising research projects in nuclear medicine to develop new treatments against cancer.

Macrocyclics, based in Dallas, Texas, is the world leader in the production of chelators*, chemical agents that allow for the attachment of antibodies or proteins with radioactive isotopes for the development of powerful nuclear medical treatments targeted against aggressive types of cancer.

“This strategic acquisition allows us to be in a unique position in the global marketplace. As a result, we can now offer new technology for attaching our isotope to antibodies targeting cancerous cells,” said Patrick Bourdet, President and CEO of AREVA Med. “The experience and the outstanding know-how of the Macrocyclics team, together with that of AREVA Med, will allow us to target more diseases and accelerate the development of radioimmunotherapy treatments using AREVA’s lead-212,” added Bourdet.

“The acquisition of our company by AREVA Med comes at an ideal time when the therapeutic power of lead-212 has been proven. By bringing our expertise with chelators to the unique competencies of AREVA Med, we will develop new powerful and targeted treatments for patients. With AREVA Med’s support, we will be able to offer an even broader range of services to our clients,” added Garry Kiefer, CEO of Macrocyclics.

In January 2011, the U.S. Food & Drug Administration (FDA) gave AREVA Med authorization to begin clinical trials for a new medicine using lead-212 to combat particularly aggressive types of cancer.

The development of new treatments in nuclear medicine is limited by the availability of isotopes. AREVA is building a new facility, the *Maurice Tubiana Laboratory*, to produce large-scale quantities of medical-grade lead-212 in the Limousin region of France.

For more information, please visit: www.aveva.com, www.avevamed.com and www.macrocyclics.com

Press Contacts

Jarret Adams
Tel.: (301) 841-1695
jarret.adams@aveva.com

Laurence Pernot
Tel.: (301) 841-1694
laurence.pernot@aveva.com

PRESS RELEASE



*A chelator is a “molecular cage” used to attach isotopes to monoclonal antibodies.

MORE ABOUT

AREVA provides its customers with solutions for carbon-free power generation in North America and all over the world. As the leader in nuclear energy and a significant, growing player in the renewable energies sector, AREVA combines U.S. and Canadian leadership, access to worldwide expertise and a proven track record of performance. Sustainable development is a core component of AREVA's strategy. Its more the 5,000 U.S. and Canadian employees work every day to make AREVA a responsible industrial player helping to supply ever cleaner, safer and more economical energy to the greatest number of people. AREVA Inc. is headquartered in Bethesda, Maryland. Visit us at <http://us.areva.com> or follow us at Twitter.

MORE ABOUT

As the leading U.S. nuclear vendor and a key player in the electricity transmission and distribution sector, AREVA Inc.'s 6,000 U.S. energy employees are committed to serving the nation and paving the way for the future of the electricity market. With 45 locations across the nation and nearly \$2 billion in energy revenues in 2008, AREVA Inc., through its subsidiaries, combines U.S. leadership, access to worldwide expertise and a proven track record of performance. In the U.S. and in more than 100 countries around the world, AREVA is engaged in the 21st century's greatest challenges: making energy available to all, protecting the planet, and acting responsibly toward future generations. AREVA Inc. is headquartered in Bethesda, Maryland.

AREVA Inc. - One Bethesda Center - 4800 Hampden Lane, Suite 1100 - Bethesda, MD 20814 T: 301 841-1600 - F: 301 841-1611